Microalbuminuria as a risk predictor in diabetes: The continuing saga

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 867-875

  Bakris, George L ^a   Molitch, Mark ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD GLUCOSE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; KIDNEY DISEASE; MICROALBUMINURIA; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); ALBUMINURIA; ANALYSIS; BLOOD; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY DISEASES; PHYSIOPATHOLOGY; RISK FACTORS; URINE;

ALBUMINURIA; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY DISEASES; PROGNOSIS; RISK FACTORS;

EID: 84896720713     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1870     Document Type: Review

References (73)

1. Keen H, Chlouverakis C. Urinary albumin excretion and diabetes mellitus. Lancet 1964;2:1155-1156
2. Keen H, Chlouverakis C, Fuller J, Jarrett RJ. The consomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guys Hosp Rep 1969;118: 247-254
3. Mogensen CE, Vittinghus E. Urinary albumin excretion during exercise in juvenile diabetes. A provocation test for early abnormalities. Scand J Clin Lab Invest 1975;35:295-300
4. Viberti GC, Jarrett RJ,McCartney M, Keen H. Increased glomerular permeability to albumin induced by exercise in diabetic subjects. Diabetologia 1978;14:293-300
5. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-1432
6. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360
7. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-689
8. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependentdiabetes. Br Med J (Clin Res Ed) 1988;296: 156-160
9. Hommel E, Mathiesen E, Edsberg B, Bahnsen M, Parving HH. Acute reduction of arterial blood pressure reduces urinary albumin excretion in type 1 (insulin-dependent) diabetic patients with incipient nephropathy. Diabetologia 1986; 29:211-215
10. Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: a step forward. Ann Intern Med 2011;154: 65-67
11. Sacks DB, Arnold M, Bakris GL, et al.; National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011;34:1419-1423
12. Deckert T, Kofoed-Enevoldsen A, Nørgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T.Microalbuminuria. Implications for micro-and macrovascular disease. Diabetes Care 1992;15:1181-1191
13. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-1418
14. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia 1998;41:694-700
15. Agewall S, Wikstrand J, Ljungman S, Fagerberg B; Risk Factor Intervention Study Group. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997;80: 164-169
16. Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010;8:604-611
17. Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010;53:49-57
18. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006;26: 635-653, vi-vii
19. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Lond) 1995;88:629-633
20. Cohen MP, Chen S, Ziyadeh FN, et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 2005;68:1554-1561
21. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996;125:201-204
22. Hoogeveen EK, Kostense PJ, Jager A, et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998;54:203-209
23. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl. 2): B54-B64
24. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res 2012;44:891-895
25. Tourigny A, Charbonneau F, Xing P, et al. CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. PLoS ONE 2012; 7:e48652
26. Wang XL, Lu JM, Pan CY, Tian H, Li CL. A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects. Diabet Med 2005;22:332-335
27. Solbu MD, Jenssen TG, Eriksen BO, Toft I. Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertensiondthe impact of microalbuminuria: a 13-year follow-up study. Metabolism 2009;58:408-415
28. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793-800
29. de Boer IH, Rue TC, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011;171:412-420
30. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008;25 (Suppl. 2):25-29
31. Rytter E, Vessby B, Asgard R, et al. Glycaemic status in relation to oxidative stress and inflammation in well-controlled type 2 diabetes subjects. Br J Nutr 2009; 101:1423-1426
32. Molitch ME, Steffes M, Sun W, et al.; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010;33:1536-1543
33. Boger CA, Chen MH, Tin A, et al.; CKDGen Consortium. CUBN is a gene locus for albuminuria. J Am Soc Nephrol 2011;22: 555-570
34. Hypertension in Diabetes Study (HDS). Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993;11: 319-325
35. Verger MF, Larpent L. Hypertensive type I diabetics have a higher level of microalbuminuria than normotensives irrespective of blood glucose equilibrium [in French]. Ann Med Interne (Paris) 1988; 139:251-253
36. Anantharaman R, Bhansali A, Bhadada SK, et al. A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy. Indian J Med Res 2011;134:658-663
37. Perkovic V, Verdon C, Ninomiya T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008;5:e207
38. Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin Pract 2011;119:c171-c177; discussion c177-c178
39. Gerstein HC, Mann JF, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426
40. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
41. Haller H, Ito S, Izzo JL Jr., et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364: 907-917
42. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992;41:836-839
43. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-1616
44. Astor BC, Matsushita K, Gansevoort RT, et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011;79:1331-1340
45. Bakris GL, Slataper R, Vicknair N, Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994;8:2-6
46. Blankestijn PJ, Derkx FH, Birkenhager JC, et al. Glomerular hyperfiltration in insulindependent diabetes mellitus is correlated with enhanced growth hormone secretion. J Clin Endocrinol Metab 1993;77:498-502
47. Ruggenenti P, Porrini EL, Gaspari F, et al.; GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012;35:2061-2068
48. Kalaitzidis R, Bakris G. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich) 2009;11:636-643
49. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989;320:966-970
50. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M; International Diabetic Nephropathy Study Group. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-2171
51. MauerM, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361: 40-51
52. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995;12:149-155
53. Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006;19:1241-1248
54. Ruggenenti P, Fassi A, Ilieva AP, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351: 1941-1951
55. Ruggenenti P, Fassi A, Ilieva A, et al.; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens 2011;29:207-216
56. Bakris GL, Sarafidis PA, Weir MR, et al.; ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-1181
57. Mann JF, Schmieder RE, McQueenM, et al.; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet 2008;372: 547-553
58. Pedersen EB, Mogensen CE. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest 1976;36:231-237
59. Mogensen CE, Christensen CK, Christensen NJ, Gundersen HJ, Gjøde P. Renal protein handling in man, modified by insulin administration, stress situations and hypertension. Int J Biochem 1980;12:181-184
60. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232
61. Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005;54:2983-2987
62. Ficociello LH, Perkins BA, Silva KH, et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2007;2: 461-469
63. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20:1069-1077
64. Rudberg S, Stattin EL, Dahlquist G. Familial and perinatal risk factors for micro-and macroalbuminuria in young IDDM patients. Diabetes 1998;47:1121-1126
65. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45-66
66. Pezzolesi MG, Jeong J, Smiles AM, et al. Family-based association analysis confirms the role of the chromosome 9q21.32 locus in the susceptibility of diabetic nephropathy. PLoS ONE 2013;8:e60301
67. Halimi JM. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab 2012; 38:291-297
68. Igo RP Jr., Iyengar SK, Nicholas SB, et al.; Family Investigation of Nephropathy and Diabetes Research Group. Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol 2011;33:381-389
69. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:462-465; discussion 466-467
70. Lambers Heerspink HJ, de ZeeuwD. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31: 458-461; discussion 468
71. Kidney Disease Improving Global OutcomesKDIGO 2012 clinical practice guideline for the evaluation and managementof chronic kidney disease. Kidney Int Suppl 2013;3:1-150
72. Luyckx VA, Bertram JF, Brenner BM, et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 2013;382:273-283
73. Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013;83:377-383